GLP-1 medications, including Ozempic, have transformed the treatment landscape for Type 2 diabetes by helping patients manage blood sugar levels, lower cardiovascular risks, and often achieve significant weight loss. However, researchers are exploring whether these physical health improvements also affect other aspects of life, such as mental health, employment, and relationships.
Read More
A working paper from the National Bureau of Economic Research, authored by Robert Kaestner and Cuiping Schiman from the University of Chicago Harris School of Public Policy, investigates this issue. The study found little evidence that among adults with diabetes, the use of GLP-1 medications led to noticeable changes in mental health, self-rated health, employment status, or marital status.
Kaestner, a research professor, noted, "We know these drugs improve health outcomes, and there’s been a great deal of research documenting those benefits. What hadn’t really been examined was whether those improvements extended into other parts of people’s lives."
As insurers and government programs consider expanding access to GLP-1 medications, understanding potential social and economic benefits is crucial. To assess this, Kaestner and Schiman analyzed over a decade's worth of data from the nationally representative Medical Expenditure Panel Survey, focusing on adults with diabetes from 2012 to 2023.
The researchers tracked the same individuals over time instead of merely comparing users and non-users of GLP-1 medications. This longitudinal approach allowed them to evaluate changes in well-being after starting treatment. Initially, differences were observed in employment and marital status between GLP-1 users and non-users. However, these discrepancies largely disappeared when examining the same individuals over time, indicating that initial differences might reflect variations in the characteristics of users versus non-users rather than medication effects.
The results indicated negligible changes in broader life outcomes, whether assessed after one year or two years of GLP-1 use. Kaestner acknowledged that this does not definitively prove that GLP-1 drugs have no impact outside of physical health. Some effects may be subtle and not easily quantified by standard measures used in the study.
"We measured outcomes like whether someone became employed or unemployed, whether they got married or divorced, and standard indicators of mental health," he said, adding that these metrics may not fully capture changes in self-esteem, relationship quality, or daily experiences.
Importantly, the findings do not undermine the established medical benefits of GLP-1 medications. Kaestner affirmed that for adults with diabetes, the most evident benefits are those confirmed through clinical research, such as improved glycemic control, weight reduction, and enhanced physical health.
As the use of GLP-1 medications expands beyond diabetes treatment and into weight management, further research may reveal additional social effects over time. "This is still a very new area of research," Kaestner stated, emphasizing the importance of understanding the implications for patients, clinicians, and policymakers as utilization grows.